BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12067986)

  • 1. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K; Wiewrodt R; Molnar-Kimber K; Jovanovic VP; Amin KM
    Cancer Res; 2002 Jun; 62(12):3438-47. PubMed ID: 12067986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
    Elliott MJ; Stilwell A; Dong YB; Yang HL; Wong SL; Wrightson WR; Martin RC; McMasters KM
    Cancer Gene Ther; 2002 May; 9(5):453-63. PubMed ID: 11961668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
    Dong YB; Yang HL; McMasters KM
    Cancer Gene Ther; 2003 Mar; 10(3):168-78. PubMed ID: 12637937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation.
    Itoshima T; Fujiwara T; Waku T; Shao J; Kataoka M; Yarbrough WG; Liu TJ; Roth JA; Tanaka N; Kodama M
    Clin Cancer Res; 2000 Jul; 6(7):2851-9. PubMed ID: 10914734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
    Majem M; Cascallo M; Bayo-Puxan N; Mesia R; Germa JR; Alemany R
    Cancer Gene Ther; 2006 Jul; 13(7):696-705. PubMed ID: 16498429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.
    Ramachandra M; Rahman A; Zou A; Vaillancourt M; Howe JA; Antelman D; Sugarman B; Demers GW; Engler H; Johnson D; Shabram P
    Nat Biotechnol; 2001 Nov; 19(11):1035-41. PubMed ID: 11689848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
    Ryan PC; Jakubczak JL; Stewart DA; Hawkins LK; Cheng C; Clarke LM; Ganesh S; Hay C; Huang Y; Kaloss M; Marinov A; Phipps SS; Reddy PS; Shirley PS; Skripchenko Y; Xu L; Yang J; Forry-Schaudies S; Hallenbeck PL
    Cancer Gene Ther; 2004 Aug; 11(8):555-69. PubMed ID: 15232601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
    Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
    Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling.
    Toth K; Djeha H; Ying B; Tollefson AE; Kuppuswamy M; Doronin K; Krajcsi P; Lipinski K; Wrighton CJ; Wold WS
    Cancer Res; 2004 May; 64(10):3638-44. PubMed ID: 15150123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
    Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
    Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
    Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
    Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53.
    Hunt KK; Deng J; Liu TJ; Wilson-Heiner M; Swisher SG; Clayman G; Hung MC
    Cancer Res; 1997 Nov; 57(21):4722-6. PubMed ID: 9354430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.
    Kamizono J; Nagano S; Murofushi Y; Komiya S; Fujiwara H; Matsuishi T; Kosai K
    Cancer Res; 2005 Jun; 65(12):5284-91. PubMed ID: 15958575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.